Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | SDHB | P21912 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CSNK1A1L | Q8N752 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465182 | 0.87 | SCD (0.56) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 | |
| SCHEMBL5500317 | 0.87 | SCD (0.54) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 | |
| SCHEMBL5597026 | 0.85 | PTGS2 (0.53) | MAPK14PTGS2ALOX5ALDH1A1CSNK1A1 | |
| SCHEMBL5144240 | 0.84 | MAPK14 (0.51) | MAPK14ALOX5ALDH1A1CSNK1A1CSNK1D | |
| SCHEMBL6440993 | 0.81 | PTGS2 (0.52) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 | |
| SCHEMBL5597148 | 0.81 | PTGS2 (0.50) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 | |
| SCHEMBL5597237 | 0.80 | PTGS2 (0.54) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 | |
| SCHEMBL8554519 | 0.79 | PTGS2 (0.47) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 | |
| SCHEMBL17002183 | 0.78 | MAPK14 (1.00) | MAPK14ALOX5ALDH1A1CSNK1A1CSNK1D | |
| SCHEMBL5501473 | 0.78 | PTGS2 (0.50) | MAPK14PTGS2PTGS1ALOX5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | PHARMACIA CORPORATION | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054646-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and an antioxidant agent for the treatment of central nervous system disorders | TXNRD2, PRDX5, PTGS2 | MAPK14 1805/4885PTGS2 3/4885PTGS1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.